Project Grant R01AI205725
Award Date 8/18/26
Completion Date 7/31/29
Dollars Obligated $654K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
South Miami, FL 33146, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Miami $457,128 on July 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop engineered probiotics that induce oral tolerance to adeno-associated virus (AAV)-delivered broadly neutralizing antibodies (BNAbs) against HIV. The project seeks to address host immune responses—specifically anti-drug antibody (ADA) responses—that limit long-term expression of AAV-delivered...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the University of Maryland Baltimore County $246,070 on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the phosphorylation and dephosphorylation of antiretroviral drugs tenofovir and emtricitabine in colonic tissue using mass spectrometry imaging-based enzyme histochemistry. The research addresses variability in clinical...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $2.454 million on July 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct longitudinal, population-based research on evolving HIV transmission dynamics and threats to epidemic control in Africa. The recipient will assess changing HIV transmission dynamics in historically generalized epidemics as they concentrate in key and priority populations, examine...
- The National Institute of Allergy and Infectious Diseases awarded the University of Miami a $6.797 million cooperative agreement on September 12, 2025, to continue and expand the STAR (Study of Treatment and Reproductive Outcomes) cohort, the largest longitudinal research platform for reproductive-age women with HIV and demographically similar women without HIV in the United States. The award funds research, mentoring, and community engagement addressing HIV, reproductive health, and chronic...
- The National Institute of Allergy and Infectious Diseases awarded New York University $841,719 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop low-cost rapid antibody tests for monitoring HIV treatment effectiveness as a complement to conventional PCR viral load testing. The research consolidates quantitative antibody data across 13 assay platforms and 17 longitudinal HIV treatment cohorts spanning 10 countries and all major HIV subtypes. The...
- The National Institute of Allergy and Infectious Diseases awarded the University of Florida $3,389,992 on June 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate chromatin remodeling complexes as modulators of HIV-1 latency and potential therapeutic targets. The research focuses on ATPase chromatin remodelers (INO80A, SMARCA5, CHD1, and CHD2) that regulate HIV transcription at distinct checkpoints during initiation, pause release, and elongation....
- The National Institute of Allergy and Infectious Diseases awarded Florida State University $800,229 on July 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop small molecule inhibitors of HIV-1 Nef-mediated immune evasion. The project targets a barrier to HIV cure: the Nef protein, which enables HIV-infected cells to evade host immunity by downregulating MHC-I and CD4 from cell surfaces, disrupting antigen presentation and allowing escape from...
- The National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services National Institutes of Health, awarded the Scripps Research Institute $937,343 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research optimizing vaccine-elicited cross-neutralizing antibody responses targeting the HIV envelope (Env) trimer apex to inform broadly neutralizing antibody (BnAb) development for...
- The National Institute of Allergy and Infectious Diseases awarded The University of Chicago $853,906 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on same-day pre-exposure prophylaxis (PrEP) initiation in emergency department settings. The research addresses a critical gap in HIV prevention: while PrEP is highly effective, uptake remains low among people at risk, particularly those with limited access to outpatient care....
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $426,823 on June 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to evaluate and refine PRISM-HIV, an artificial intelligence–driven, case-based learning platform designed to address the HIV clinical workforce shortage in the United States. PRISM-HIV is a large language model–based educational tool that simulates faculty-guided interactive HIV case scenarios to build...